Pages

Tuesday, January 10, 2012

FDA is advising healthcare professionals and patients of a potential problem with opiate products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Nebraska manufacturing site. Due to problems that occurred when these products were packaged and labeled at the site, tablets from one product type may have carried over into packaging of another product. This could result in a stray pill of one medicine ending up in the bottle of another product.

The following products are included:

Opana ER (oxymorphone hydrochloride) Extended-Release Tablets CII

Opana (oxymorphone hydrochloride) CII

Oxymorphone hydrochloride Tablets CII

PERCOCET (oxycodone hydrochloride and acetaminophen USP) Tablets CII

PERCODAN (oxycodone hydrochloride and aspirin, USP) Tablets CII

ENDOCET (oxycodone hydrochloride and acetaminophen USP) Tablets CII

ENDODAN (oxycodone hydrochloride and aspirin, USP) Tablets CII

MORPHINE SULFATE Extended-Release Tablets CII

ZYDONE (hydrocodone bitartrate/acetaminophen tablets, USP) CIII

Please be sure to check the contents of your prescriptions carefully. All of the pills in the bottle should look the same. If the pills don't look like what you normally take or if you find any pills that are different in shape, size, color, or markings, take them to your pharmacist right away.

Endo Pharmaceuticals has provided a visual guide of the affected drugs that you can download if you would like to double check the tablets in your prescription: Endo Pharmaceuticals Opioid Guide.

Disclaimer: Nothing on this blog is intended as medical or legal advice.

What I write on this site is my own, and if it is someone else's, I take special care to attribute it to the original author. So, please don't use any of my material without proper attribution or permission. Thanks.